David Rhinesmith


Washington, D.C.

David's practice focuses on government investigations, regulatory enforcement matters, complex civil litigation, internal investigations, and white-collar criminal defense.  David has particular experience representing companies and individuals in the life sciences, health care, technology, energy, and financial services sectors.

David has represented clients in matters involving state and federal false claims acts, the Anti-Kickback Statute, federal securities laws, the Foreign Corrupt Practices Act (FCPA), anti-money laundering laws, and the Food, Drug, & Cosmetic Act.  He has played a lead role in high-stakes federal investigations, complex civil cases, and criminal matters.  His litigation experience includes oral argument before the First Circuit, briefing in federal and state courts, and deposing senior government officials.  And he draws on this experience to advise clients on potential enforcement risks and regulatory issues.

David served as Global Investigations & Compliance Counsel (on secondment) at one of the world's leading medical device companies, immediately following one of the industry's largest mergers.  In this role he led multiple internal investigations and helped the company develop a new investigations and corporate compliance function. 

David previously worked as an Assistant Attorney General in the Appeals Division of the Massachusetts Attorney General’s Office (as part of a one-year fellowship), serving as lead counsel in more than a dozen criminal and civil matters at all levels of federal and state court.  David was also an associate in the Chicago and Washington, D.C. offices of another international law firm.

In 2017, 2018, 2019, and 2020 David was selected to the Washington, D.C. Super Lawyers Rising Stars list.

    • Counsel to the independent compliance monitors appointed by the DOJ and SEC as part of the resolution of major FCPA investigation.
    • Represented multinational defense contractor in billion dollar False Claims Act litigation.
    • Advised life sciences companies on restructuring board and physician arrangements.
    • Represented national health care provider in challenging new regulations.
    • Represented educational institution in criminal investigation.
    • Negotiated comprehensive civil resolution for diagnostic laboratory to resolve wide-ranging federal investigation, including alleged anti-kickback, Stark law, and false claims act violations.
    • Represented several leading health care companies in civil qui tam litigation.
    • Represented multinational medical device company in major government-initiated FCPA investigation.
    • Represented leading pharmaceutical company in federal health care fraud investigation alleging off-label marketing and False Claims Act violations.
    • Conducted and led multiple internal investigations for medical device company concerning potential FCPA and anti-money laundering violations.
    • Conducted and led multiple internal investigations for health care company concerning potential violations of federal health care laws.
    • Represented leading national health care company in federal and state qui tam cases alleging improper referrals.
    • Represented international pharmaceutical company in federal and state qui tam cases related to marketing practices and alleged off-label promotion.
    • Represented executive in SEC investigation into alleged accounting fraud, securing full immunity.
    • Counseled private investment firm in responding to SEC audit, resulting in a finding of no violations.